BASIC// DISCOVERY

VACCINES FIGHTING
VIRUSES & CANCER

Matthias Schnell, PhD, and his team
are developing vaccines to fight
diseases like Ebola, Lassa Fever
and COVID-19.
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A GROUP OF JEFFERSON VIRAL VACCINE RESEARCHERS LED
by Jefferson Vaccine Center (JVC) director
and professor of microbiology and immunology
Matthias Schnell, PhD have been using rabies
vaccine as a potent tool for understanding and
fighting hemorrhagic viruses—such as Ebola,
Marburg, Sudan and Lassa Feve—as well as
coronavirus. By the end of 2019, the team had
developed a tetravalent vaccine that uses an
established dead-virus rabies vaccine modified with
specific antigens for the viruses. In animal models,
the immune system develops a reaction to the
vaccine that is specific and can defend against
rabies and some viruses. Soon after COVID-19
first emerged, Schnell and his team created a
killed-rabies vaccine that incorporates the spike
portion of the SARS-COV-2 virus, which causes
the disease. The resulting COVID-19 vaccine
candidate—CORAVAX™—was put into animal trials
as a prelude to expected phase 1 clinical trials.

The importance of leveraging
our approach to create a

coronavirus vaccine
candidate is clear.
“Rabies is a prevalent problem in much of the
world, and it is extremely hard to prevent spread
of hemorrhagic viruses—evidenced by the most
recent Ebola outbreak. It would be valuable
to be able to provide immunity against these
diseases simultaneously,” Dr. Schnell says. "And
the importance of leveraging our approach to
create a coronavirus vaccine candidate is clear."
The NIH-funded project involves a bench-tobedside range of work: From identifying and
applying the antigens and observing the quality
of the antibody response to developing a
scalable production process to planning clinical
trials. With the vaccine having proved effective
and safe in small and large animal models, Dr.
Schnell’s team is working with a production
facility to ensure Good Manufacturing Processes
of the vaccine formulation. That process, which
should be completed in the coming year, will
be prelude to a subsequent phase I clinical
trial testing toxicity. If early clinical trials are
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successful, the vaccine could be ready to test
in actual disease outbreaks within five years.
JVC is the cornerstone of the University's
programmatic research in immunology and
infection disease. Building on basic and translational
studies in immunology, microbial pathogenesis
and tumor immunology, JVC researchers
pursue multifaceted investigations on vaccines
that combat viruses and those that provoke
immune response to diseases such as cancer.
JVC researchers are also seeing robust results
from their rabies-based vaccine for Nipah virus,
which is transmitted from animals to humans
and causes severe respiratory illness that can
progress into encephalitis, seizure and coma.
Outbreaks have occurred in Malaysia, Singapore,
Bangladesh and India; and because no vaccine is
available, the World Health Organization has listed
Nipah as needing urgent action. A recent study in
mice—testing a rabies vector that incorporates a
Nipah virus gene—showed that one dose of the
vaccine was safe and elicited strong antibodies
response against both Nipah and rabies. A
second, chemically killed version of the vaccine—
which could be ideal for immunocompromised
individuals—also safely induced strong immunity.
Rabies’ unique method for attacking the brain—it
bypasses the blood system and the blood-brain barrier
by entering the central nervous system (CNS) through
muscles at the site of an infecting bite—makes it a
perfect tool to learn about ways of harnessing the
power of the immune system to fight tumors in the
brain. Results from recent studies by JVC investigators
found that delivering rabies vaccine through a
mouse’s jaw muscles promoted an immune response
in the brain—one sufficient to prompt CNS immune
memory and protect against rabies in a way current
vaccines do not. The study also demonstrated
that for immune mechanisms to properly protect
the brain long-term, immune “memory” cells
must become resident in the CNS. That suggests
immunity established in the blood is insufficient to
fight brain cancer—a potentially pivotal finding for
development of vaccines against the disease.
That study was one in a series of projects in which
Jefferson researchers are translating their basic
science discoveries into immune-based cancer
treatments that have proven effective in early trials.
See Advancing Cellular and Immune-based Cancer
Therapies on page 6 for a look at that work. 
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